Date | Title | Description | |
---|---|---|---|
24 Feb 2021 | About corporate governance | The Company informs about the agreements adopted by the Board of Directors | Download |
27 Nov 2020 | On business and financial situation | The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia | Download |
09 Jul 2020 | On business and financial situation | ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate | Download |
Pages
Date | Title | Description | |
---|---|---|---|
21 Oct 2021 | On business and financial situation | The Company informs of the delay in the decision on Risperidone ISM® by the U.S. Food and Drug Administration (“FDA”). | Download |
07 Oct 2021 | Liquidity and counterparty agreements | Download | |
04 Oct 2021 | Liquidity and counterparty agreements | Download | |
01 Sep 2021 | On business and financial situation | ROVI informs about the joint statement from Moderna and Takeda on the investigation of suspended lots of the vaccine | Download |
28 Jul 2021 | On business and financial situation | ROVI releases the first half 2021 results presentation | Download |
Pages
Date | Title | Description | |
---|---|---|---|
08 May 2019 | Information on P&L | ROVI releases the first quarter 2019 results presentation | Download |
08 May 2019 | Information on P&L | ROVI releases the press release related to the first quarter 2019 financial results | Download |
07 May 2019 | Liquidity contracts and specialists | ROVI announces the signature of a new liquidity contract with Renta 4 Banco, S.A. | Download |
30 Apr 2019 | Liquidity contracts and specialists | ROVI announces the termination of the liquidity contract signed with JB Capital Markets, S.V., S.A.U. | Download |
11 Apr 2019 | Strategic agreements with third parties | The Company releases the press release related to the marketing agreement of Tetridar® in Spain | Download |